纤溶酶原激活物 plasminogen activator英语短句 例句大全

纤溶酶原激活物,plasminogen activator

1)plasminogen activator纤溶酶原激活物

1.Correlation ofplasminogen activator and plasminogen active inhibitor expression and capillary density in IgA nephropathy.;纤溶酶原激活物及其抑制剂-1表达与IgA肾病毛细血管密度相关关系的研究

2.The relationship between the dynamic change of plasmaplasminogen activator and its inhibitor-1 levels and infarct size in patients with acute cerebral infarction;急性脑梗死患者血浆纤溶酶原激活物及其抑制剂-1水平的动态变化及其与梗死面积的关系

3.Detection of Plasminogen activator and thrombomodulin in lung cancer patients and its clinical significance;肺癌患者纤溶酶原激活物和血栓调节蛋白检测分析

英文短句/例句

1.Relationship between plasminogen activator inhibitor 1 and neuroblastoma纤溶酶原激活物抑制物1与神经母细胞瘤

2.Plasma Concentrations Changes and Significance of Plasminogen Activator, Plasminogen Activator Receptor and Plasminogen Activator Inhibitor-1 in Chronic Glomerulonephritis and the Intervenient Research on Them;慢性肾小球肾炎血浆纤溶酶原激活物及其受体和纤溶酶原激活物抑制剂的变化与干预研究

3.Preliminary Study on DNA Family Shuffling of Tissue-type Plasminogen Activator Genes;组织型纤溶酶原激活物DNA改组的探索研究

4.Plasminogen Activator Inhibitor-1 and Cardiovascular Diseases纤溶酶原激活物抑制剂-1与心血管疾病

5.Inhibitory effect of green tea polyphenols on plasminogen activator inhibitor-1 expression绿茶多酚对纤溶酶原激活物抑制剂-1表达影响

6.Clinical Significance of Measurement of Plasma Urokinase Type Plasminogen Activator and its Receptor in Cancer Patients癌症患者尿激酶型纤溶酶原激活物及其受体检测的临床意义

7.The Relationship between the Expression of Yrokinase-type Plasminogen Activator Receptor,and the Infiltration and Metastasis of Gastric Cancer尿激酶型纤溶酶原激活物受体表达与胃癌浸润和转移过程的关系

8.Expression of urokinase-type plasminogen activator and its receptor protein in synovial tissues from osteoarthritis骨关节炎滑膜中尿激酶型纤溶酶原激活物及其受体蛋白的表达

9.Study on the Transcriptional Regulation of Urokinase Plasminogen Activator in Human Lung Cancer;尿激酶型纤溶酶原激活物在人肺癌细胞中表达调控的研究

10.The Experiment Research That the uPA to Suffer from the Relativity with the Arthritis Disease;尿激酶型纤溶酶原激活物（uPA）与关节炎性疾患相关性的实验研究

11.Expressions of Survivin and uPA in human cerebral gliomas脑胶质瘤组织中Survivin和尿激酶型纤溶酶原激活物蛋白的表达

12.Intravenous thrombolytic therapy with recombinant-tissue plasminogen activator for super early stage of cerebral infarction重组组织型纤溶酶原激活物rt-PA静脉溶栓治疗超早期脑梗死

13.The Role of the Plasminogen Activator Inhibitor-1 in the Pathogenesis of Hepatic Fibrosis;纤溶酶原激活物抑制剂-1在肝纤维化发生中的作用

14.Relationship between the Changes of Activity of Tissue-Type Plasminogen Activator on Brains and Cerebral Edema in Asphyxia Status of Mice窒息鼠脑组织型纤溶酶原激活物活性变化与脑水肿的关系

15.Effects of Qinggan Huoxue Recipe and its separated recipes on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 fibrinolytic system in rats with alcoholic liver fibrosis清肝活血方及其拆方对酒精性肝纤维化大鼠尿激酶型纤溶酶原激活物途径的影响

16.Change and Implication of PAI-1 in Coronary Heart Disease Patients after Glucose Load冠心病患者糖负荷后纤溶酶原激活物抑制物-1的变化及意义

17.Detection and clinical significance of plasma urokinase-type plasminogen activator and its soluble receptor in multiple myeloma patients;多发性骨髓瘤患者血浆尿激酶型纤溶酶原激活物及其可溶性受体的检测

18.Cytokine-induced release of plasminogen activator inhibitor-1 by human pleural mesothelial cells细胞因子诱导人胸膜细胞释放纤溶酶原激活物抑制剂-1的研究

相关短句/例句

activator of plasminogen纤溶酶原激活物

1.Effects of NaoMaiTong combined with thrombolysis onactivator of plasminogen and its receptor in rats with thrombus-occluded cerebral ischemia;脑脉通联合溶栓对血栓栓塞性脑缺血大鼠纤溶酶原激活物及其受体的影响

3)urokinase-type plasminogen activator尿激酶纤溶酶原激活物

1.Aim: To investigate the expression ofurokinase-type plasminogen activator (uPA) in human colorectal carcinoma tissue and its relation to the neovascularization.目的检测大肠癌组织中尿激酶纤溶酶原激活物(uPA)及微血管密度(MVD)。

2.The protein level ofurokinase-type plasminogen activator (uPA) was also determined by western blotting.采用Western blot方法检测癌细胞尿激酶纤溶酶原激活物(uPA)蛋白水平。

3.Besides,the protein level ofurokinase-type plasminogen activator(uPA) was also determined by Western blot assay.另外,采用Western blot方法检测癌细胞尿激酶纤溶酶原激活物(urokinase-type plasminogen activator,uPA)蛋白变化。

4)plasminogen activator inhibitor-1纤溶酶原激活物抑制物

1.Objective:To analyze the plasma levels of tissue plasminogen activator(t-PA) andplasminogen activator inhibitor-1(PAI-1) in patients with coronary heart disease(CHD) and to assess its clinical implications.方法:回顾性分析本院222例冠心病患者血浆组织型纤溶酶原激活物(t-PA)及纤溶酶原激活物抑制物-1(PAI-1)水平。

2.ObjectiveTo evaluate the plasminogen activator system (plasminogen activator inhibitor-1 and tissue plasminogen activator) in women with PCOS and compared in groups .目的:探讨纤溶酶原激活物抑制物-1(PAI-1)和组织型纤溶酶原激活物(t-PA)的高低与多囊卵巢综合征(polycystic ovary syndrome, PCOS)患者病变发展之间的关系以探寻一较好的监测指标。

3.Objective To investigate the role of rosiglitazone in improving blood lipids and proteinuria in rats with Type 2 diabete,and the effect of rosiglitazone on expressions ofplasminogen activator inhibitor-1 in kidney of streptozotocin-diabetic rats.目的研究罗格列酮对2型糖尿病大鼠血糖血脂的影响及肾皮质纤溶酶原激活物抑制物1(PAI-1)表达的作用。

5)plasminogen activator inhibitor纤溶酶原激活物抑制物

1.Objective To observe the influence of Shenluotong on the protein expression ofplasminogen activator inhibitor 1(PAI-1) in kidney remaining tissue in rats with kidney failure induced by 5/6 of nephrectomy.目的观察肾络通对5/6肾切除肾衰竭大鼠残余肾组织纤溶酶原激活物抑制物-1(PAI-1)蛋白表达的影响。

2.The activities of tissue plasminogen activator(tPA),plasminogen activator inhibitor(PAI) and plasminogen(PLG) in plasma were determined by chromogenic substrate assay,and thrombi weight was measured.先给大鼠喂药后以FeCl3诱导左侧颈总动脉血栓形成,以发色底物法测定血浆组织型纤溶酶原激活物(tPA)、纤溶酶原激活物抑制物(PAI)和纤溶酶原(PLG)活性,并测定血栓质量。

3.Objective To investigate the changes of serumplasminogen activator inhibitor(PAI),D-dimer and thrombomodulin(TM),and the relationship between these changes and phlegm syndrome or blood-stasis syndrome in patients with acute cerebral infarction.目的探讨急性脑梗死患者血浆纤溶酶原激活物抑制物(PAI)、D-二聚体、血栓调节蛋白(TM)变化与中医痰证、血瘀证变化的关系。

6)Plasminogen activator inhibitor 1纤溶酶原激活物抑制物

1.Objective To study the changes of tissue plasminogen activator (t-PA), plasminogen activator inhibitor 1 (PAI-1), and soluble thrombomodulin (sTM) induced by dengue 2 virus (D 2V) infection of vascular endothelial cells.方法应用D2 V感染生长良好的第2、3代脐静脉内皮细胞以观察内皮细胞在表达组织纤溶酶原激活物(tPA)、纤溶酶原激活物抑制物1(PAI 1)、凝血酶调节蛋白(TM)等分子变化。

延伸阅读

纤溶酶原激活剂分子式：CAS号：性质：是一组蛋白酶，使纤溶酶激活生成有活性的纤溶酶。它们主要包括：(1)组织纤溶酶激动剂(tPA)，一种丝氨酸蛋白酶，创伤或应激时从血管内皮释放入血，只有同纤维蛋白结合时才有激活纤溶酶原的活性；(2)尿激酶，对纤维蛋白选择性较低，是某些内皮细胞系合成、经外分泌管道(如肾小管)分泌，可能参与清除沉积在管道内的纤维蛋白；(3)链激酶，临床上用于裂解纤维蛋白，其选择性较差，可作用于液相中的纤溶酶原，也可作用于纤维蛋白血块中的纤溶酶原，链激酶不是蛋白酶，但与纤溶酶原结合成复合物后构象改变，显示蛋白水解酶活性。